Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharma company Regeneron Pharmaceuticals
So what: Positive study data is pretty much always music to the ears of biopharma investors. In Regeneron's case, the company -- along with partner sanofi-aventis
Now what: Commenting on the results, Regeneron's chief scientific officer said that Regeneron and sanofi-aventis will now submit applications for marketing approval for Zaltrap to the U.S. Food and Drug Administration and the European Medicines Agency in the second half of the year. Investors in sanofi-aventis hardly blinked at the news, as the market for Zaltrap is relatively modest. However, for a smaller company like Regeneron, the impact of an approval (which is still far from guaranteed) would be more significant.
Want to keep up to date on these stocks?